Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993
Ann Oncol. 2021 Oct;32(10):1308.
doi: 10.1016/j.annonc.2021.07.013.
Epub 2021 Aug 2.